TRAMP-C2 murine prostate cancer cells, with impaired STING expression acquired with CRISPR-Cas9 technology, were characterized by a lower rate of rejection in short-term rejection assays in comparison with their wild-type counterparts. The gene discussed is STING1; the disease is prostate carcinoma.